Marstacimab
- Generic Name
- Marstacimab
- Drug Type
- Biotech
- CAS Number
- 1985638-39-8
- Unique Ingredient Identifier
- 0UB3OA67O7
- Background
Marstacimab is a human Monoclonal Antibody Directed Against Tissue Factor Pathway Inhibitor currently being developed by Pfizer for the treatment of hemophilia A and hemophilia B.
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT06703606
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT05611801
- Locations
- 🇺🇸
Intermountain - Primary Children's Hospital, Salt Lake City, Utah, United States
🇦🇷Arbesu Hematología, Mendoza, Argentina
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 245
- Registration Number
- NCT05145127
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Northwell Health HTC, New Hyde Park, New York, United States
🇺🇸Washington Institute for Coagulation d/b/a WACBD, Seattle, Washington, United States
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT04832139
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 186
- Registration Number
- NCT03938792
- Locations
- 🇺🇸
Washington Institute for Coagulation, Seattle, Washington, United States
🇨🇳Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇺🇸USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.